These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16239061)

  • 1. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.
    Campbell IG; Eccles DM; Choong DY
    Cancer Lett; 2006 Aug; 240(2):195-7. PubMed ID: 16239061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
    Wasielewski M; Nagel JH; Brekelmans C; Klijn JG; van den Ouweland A; Meijers-Heijboer H; Schutte M
    Breast Cancer Res Treat; 2007 Aug; 104(2):153-7. PubMed ID: 17080308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
    Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
    Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
    BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
    Economopoulos KP; Sergentanis TN
    Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
    Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
    Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
    Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
    BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
    Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
    BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.
    Krekac D; Brozkova K; Knoflickova D; Hrstka R; Muller P; Nenutil R; Vojtesek B
    Oncology; 2008; 74(1-2):84-7. PubMed ID: 18547962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
    Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
    Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
    Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
    Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
    J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS; Miller CW; Karlan BY; Koeffler HP
    Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
    Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
    Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.
    Wo X; Han D; Sun H; Liu Y; Meng X; Bai J; Chen F; Yu Y; Jin Y; Fu S
    J Genet Genomics; 2011 Aug; 38(8):341-50. PubMed ID: 21867960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.
    Lum SS; Chua HW; Li H; Li WF; Rao N; Wei J; Shao Z; Sabapathy K
    Carcinogenesis; 2008 Apr; 29(4):754-61. PubMed ID: 18281248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 SNP309 and cancer risk: a combined analysis.
    Wilkening S; Bermejo JL; Hemminki K
    Carcinogenesis; 2007 Nov; 28(11):2262-7. PubMed ID: 17827408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.